HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neutrogena estimates costs from FDA's OTC label reg compliance could reach $38 mil..

This article was originally published in The Rose Sheet

Executive Summary

NEUTROGENA FINANCIAL BURDEN FROM OTC LABEL REG COMPLIANCE WOULD REACH $38 MIL., the Johnson & Johnson skin and hair care subsidiary states in Oct. 1 comments on FDA's proposed OTC labeling revisions. The $38 mil. figure includes "administrative and production costs, component scrap and projected retail returns of merchandise due to relabeling," the company states. FDA has estimated relabeling costs to industry to reach $19.8 mil., while the Nonprescription Drug Manufacturers Association places the figure at $140 mil. if implemented over a two-year period or $70 mil. over a three-year period ("The Rose Sheet" Oct. 13, p. 8).
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004762

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel